{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T17:41:07Z","timestamp":1781113267993,"version":"3.54.1"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.ejmech.2025.118116","type":"journal-article","created":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T22:28:47Z","timestamp":1757284127000},"page":"118116","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Development of a P2X3 receptor antagonist derived from eliapixant with improved properties for the treatment of chronic cough"],"prefix":"10.1016","volume":"300","author":[{"given":"Yang","family":"Zang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohua","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruibin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lifei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongna","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihan","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-2628-0279","authenticated-orcid":false,"given":"Xuejun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2025.118116_bib1","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s00424-006-0070-9","article-title":"Pharmacology of P2X channels","volume":"452","author":"Gever","year":"2006","journal-title":"Pfluegers Arch."},{"key":"10.1016\/j.ejmech.2025.118116_bib2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s11302-011-9271-6","article-title":"In pursuit of P2X3 antagonists: novel therapeutics for chronic pain and afferent sensitization","volume":"8","author":"Ford","year":"2012","journal-title":"Purinergic Signal."},{"key":"10.1016\/j.ejmech.2025.118116_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2022.108166","article-title":"Treatment of chronic cough: P2X3 receptor antagonists and beyond","volume":"237","author":"Sykes","year":"2022","journal-title":"Pharmacol. Therapeut."},{"key":"10.1016\/j.ejmech.2025.118116_bib4","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s11302-011-9272-5","article-title":"P2X receptor antagonists for pain management: examination of binding and physicochemical properties","volume":"8","author":"Gum","year":"2012","journal-title":"Purinergic Signal."},{"key":"10.1016\/j.ejmech.2025.118116_bib5","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1007\/s13311-020-00934-2","article-title":"P2X3-containing receptors as targets for the treatment of chronic pain","volume":"17","author":"Krajewski","year":"2020","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.ejmech.2025.118116_bib6","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1093\/humrep\/deaa061","article-title":"Activation of ATF3\/AP-1 signaling pathway is required for P2X3-induced endometriosis pain","volume":"35","author":"Ding","year":"2020","journal-title":"Hum. Reprod."},{"key":"10.1016\/j.ejmech.2025.118116_bib7","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0184647","article-title":"P2X3 receptor involvement in endometriosis pain via ERK signaling pathway","volume":"12","author":"Ding","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2025.118116_bib8","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s00408-023-00606-w","article-title":"The efficacy and safety of gefapixant in a phase 3b trial of patients with recent-onset chronic cough","volume":"201","author":"McGarvey","year":"2023","journal-title":"Lung"},{"key":"10.1016\/j.ejmech.2025.118116_bib9","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s00408-023-00621-x","article-title":"Efficacy and safety of eliapixant in refractory chronic cough: the randomized, placebo controlled phase 2b PAGANINI study","volume":"201","author":"Dicpinigaitis","year":"2023","journal-title":"Lung"},{"key":"10.1016\/j.ejmech.2025.118116_bib10","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s00408-022-00592-5","article-title":"A randomized, double-blind, placebo-controlled, parallel-group phase 2b trial of P2X3 receptor antagonist sivopixant for refractory or unexplained chronic cough","volume":"201","author":"McGarvey","year":"2023","journal-title":"Lung"},{"key":"10.1016\/j.ejmech.2025.118116_bib11","first-page":"807","article-title":"Efficacy in SOOTHE, a phase 2b trial of BLU-5937 in refractory chronic cough, was not dependent of taste disturbance adverse events","volume":"60","author":"Birring","year":"2022","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.ejmech.2025.118116_bib12","doi-asserted-by":"crossref","first-page":"14443","DOI":"10.1021\/acs.jmedchem.4c01214","article-title":"Discovery of triazolopyrimidine derivatives as selective P2X3 receptor antagonists binding to an unprecedented allosteric site as evidenced by cryo-electron microscopy","volume":"67","author":"Kim","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118116_bib13","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.bmcl.2009.02.003","article-title":"Identification and SAR of novel diaminopyrimidines Part 1: the discovery of RO-4, a dual P2X(3)\/P2X(2\/3) antagonist for the treatment of pain","volume":"19","author":"Carter","year":"2009","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2025.118116_bib14","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1016\/S0140-6736(14)61255-1","article-title":"P2X3 receptor antagonist (AF-219) in refractory chronic cough: a randomised, double-blind, placebo-controlled phase 2 study","volume":"385","author":"Abdulqawi","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2025.118116_bib15","doi-asserted-by":"crossref","first-page":"267","DOI":"10.3389\/fncel.2013.00267","article-title":"The therapeutic promise of ATP antagonism at P2X3 receptors in respiratory and urological disorders","volume":"7","author":"Ford","year":"2013","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.ejmech.2025.118116_bib16","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-99177-0","article-title":"Eliapixant is a selective P2X3 receptor antagonist for the treatment of disorders associated with hypersensitive nerve fibers","volume":"11","author":"Davenport","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2025.118116_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2021.128384","article-title":"Discovery of clinical candidate Sivopixant (S-600918): lead optimization of dioxotriazine derivatives as selective P2X3 receptor antagonists","volume":"52","author":"Kai","year":"2021","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2025.118116_bib18","first-page":"56","article-title":"BLU-5937: a selective P2X3 antagonist with potent anti-tussive effect and no taste alteration, Pulmonary","volume":"56","author":"Garceau","year":"2019","journal-title":"Pharmacol. Therapeut."},{"key":"10.1016\/j.ejmech.2025.118116_bib19","series-title":"London International Cough Symposium","article-title":"Phase 2 RELIEF trial of BLU-5937 for the treatment of refractory chronic cough","year":"2021"},{"key":"10.1016\/j.ejmech.2025.118116_bib20","first-page":"3800","article-title":"Two phase 3 randomized clinical trials of Gefapixant, a P2X3 receptor antagonist, in refractory or unexplained chronic cough (COUGH-1 and COUGH-2)","volume":"56","author":"McGravey","year":"2020","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.ejmech.2025.118116_bib21","series-title":"Analogues of 3-(5-methyl-1,3-thiazol-2-yl)-N-{(1R)-1-[2-(trifluoro-methyl)pyrimidine-5-yl]ethyl}benzamide","author":"Rottmann","year":"2020"},{"key":"10.1016\/j.ejmech.2025.118116_bib22","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s41586-024-07487-w","article-title":"Accurate structure prediction of biomolecular interactions with AlphaFold 3","volume":"630","author":"Abramson","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2025.118116_bib23","article-title":"Boltz-2: towards accurate and efficient binding affinity prediction","author":"Passaro","year":"2025","journal-title":"bioRxiv"},{"key":"10.1016\/j.ejmech.2025.118116_bib24","author":"Wohlwend","year":"2024","journal-title":"bioRxiv"},{"key":"10.1016\/j.ejmech.2025.118116_bib25","doi-asserted-by":"crossref","first-page":"4939","DOI":"10.1073\/pnas.1800907115","article-title":"Druggable negative allosteric site of P2X3 receptors","volume":"115","author":"Wang","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"10.1016\/j.ejmech.2025.118116_bib26","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41592-022-01488-1","article-title":"ColabFold: making protein folding accessible to all","volume":"19","author":"Mirdita","year":"2022","journal-title":"Nat. Methods"},{"key":"10.1016\/j.ejmech.2025.118116_bib27","author":"Schr\u00f6dinger"},{"key":"10.1016\/j.ejmech.2025.118116_bib28","series-title":"Rdkit\/Rdkit: 2024_03_5","author":"Landrum","year":"2024"},{"key":"10.1016\/j.ejmech.2025.118116_bib29","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s13321-021-00522-2","article-title":"Gnina 1.0: molecular docking with Deep Learning","volume":"13","author":"McNutt","year":"2021","journal-title":"J. Cheminf."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425008815?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425008815?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T15:20:48Z","timestamp":1760023248000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523425008815"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":29,"alternative-id":["S0223523425008815"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118116","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of a P2X3 receptor antagonist derived from eliapixant with improved properties for the treatment of chronic cough","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118116","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118116"}}